| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Revenue | ||||||
2,764 | 12,434 | 291 | 634 | - | - | - |
Revenue | ||||||
- | - | - | - | 519 | 1,549 | 976 |
Operating expenses: | ||||||
Research and development | ||||||
15,119 | 23,035 | 39,640 | 44,953 | 27,237 | 17,378 | 22,293 |
Research and development – related party | ||||||
- | - | - | 795 | 2,347 | 1,351 | 3,141 |
General and administrative | ||||||
8,537 | 9,223 | 11,333 | 9,906 | 9,077 | 11,717 | 11,375 |
Total operating expenses | ||||||
23,656 | 32,258 | 50,973 | 55,654 | 38,661 | 30,446 | 36,809 |
Operating loss | ||||||
-20,892 | -19,824 | -50,682 | -55,020 | -38,142 | -28,897 | -35,833 |
Other income | ||||||
1 | 46 | - | -22 | -838 | -503 | 41 |
Other (expense) income – related party | ||||||
827 | -638 | -190 | - | -392 | -623 | -575 |
Interest income | ||||||
53 | 61 | 117 | 87 | 40 | 4 | - |
Interest expense | ||||||
1,827 | 3,290 | 3,092 | 398 | 108 | 286 | 476 |
Interest expense, net related party | ||||||
- | - | - | - | 1,667 | 5,727 | 11,346 |
Investment loss related party | ||||||
- | - | - | - | - | -69 | -14 |
Loss before income taxes and noncontrolling interest | ||||||
-21,838 | -23,645 | -53,847 | -55,353 | -41,107 | -36,101 | -48,203 |
Income tax provision | ||||||
100 | 200 | 800 | 0 | 0 | 0 | - |
Net loss before noncontrolling interest | ||||||
-21,938 | -23,845 | -54,647 | -55,353 | -41,107 | -36,101 | -48,203 |
Less: net loss attributable to noncontrolling interest | ||||||
-8,894 | -15,934 | -38,503 | -39,001 | -13,609 | - | - |
Net loss attributable to vTv Therapeutics Inc. | ||||||
-13,044 | -7,911 | -16,144 | -16,352 | -27,498 | -36,101 | -48,203 |
Net loss attributable to vTv Therapeutics Inc. common shareholders | ||||||
-17,913 | -8,650 | -16,144 | -16,352 | - | - | - |
Class A Common Stock [Member] | ||||||
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted | ||||||
-0.59 | -0.69 | -1.67 | -1.71 | - | - | - |
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted | ||||||
30,292 | 12,449 | 9,693 | 9,545 | - | - | - |